Have you had a medication that you could not afford lately?

If you answered yes, you probably are not alone. The cost of certain prescriptions, like those for hepatitis C, cancer and rheumatoid arthritis, have skyrocketed. Many of these special drugs cannot be accessed from a regular retail pharmacy. The patient must acquire the treatment from a “specialty pharmacy”, that may not even be in their […]

Drugs.com Reaches 500,000 Facebook Likes

fb500

Drugs.com has topped the 500,000 likes mark on our Facebook page. A huge thank you to the half million dedicated fans who follow our page, like our articles and share our links. We appreciate every single one of you. It is our aim to keep you up-to-date on all things drug related through our daily […]

Drug Shortages: Has the FDA Response Made an Impact?

Rationing of much needed medications for patients is a scary thought for me as a healthcare professional. I can understand when an orphan drug may go in short supply for a rare disease, but when commonly used medications like antibiotics and intravenous fluids become scarce, I wonder what the forces are that cause this to […]

Harnessing the Power of the Poliovirus as a Cancer Cure

brain_tumor

Polio, a highly infectious and crippling disease, was certainly one of the most feared viruses in the 20th century. Each year, thousands of children were left paralyzed. Polio has been successfully eliminated in the U.S. for decades due to a widespread vaccine program. So why would a group of researchers be interested in injecting the […]

Biosimilars in 2015: What Can We Expect?

On Friday, March 6th, 2015 the FDA approved Sandoz’s Zarxio, the first official biosimilar that will be made available in the U.S. Zarxio, a recombinant granulocyte colony-stimulating factor used to boost white blood cells after cancer treatments, is the long-awaited biosimilar for filgrastim (Amgen’s Neupogen). The FDA noted in their briefs that Zarxio was “highly […]

Drugs.com Adds Mayo Clinic Disease Reference

Drugs.com is pleased to announce it has licensed select content from Mayo Clinic to provide more timely and trustworthy medical condition and disease information. The articles include detailed information about medical diseases such as allergies, back pain, depression, erectile dysfunction, and type 2 diabetes. Each article includes informative sections which may include an overview, symptoms, when […]

Fox News Features Drugs.com Medication Guide app

Thanks to Fox News for showcasing the Drugs.com Medication Guide app today. Very much appreciated. Available in both the Apple App store and the Google Play store, this is a great app for ultra-quick research and/or keeping track of multiple meds. Check out the video at the link below… http://www.foxnews.com/health/2014/07/13/drugscom-app-provides-medical-information-on-go/ And check out the apps here… http://www.drugs.com/apps/

Consumer Reports Gives the Thumbs Up to the Drugs.com Pill Identifier App

screen568x568

Consumer Reports just put out a review of seven pill identifier apps. Here’s a snippet… “We reviewed seven apps that can help identify the pills you take, and liked two of them a lot: Drugs.com Pill Identifier and Epocrates Pill ID. The others—CVS/Pharmacy Pill Identifier, iPharmacy Pill Identifier, Pill Finder, Prescription Pill Identifier, and ID […]

Introducing the Drugs.com redesign

drugs_icon_050314

After a lot of effort from our NY brand agency and in-house designers, we have started to roll out a new look for Drugs.com. First step is a logo and menu change. At the same time we have a team working through updating all the mobile apps, Facebook, Google+, Twitter and Youtube channels. Wow, we’re […]

Q4 2013 Drug Sales Data Released: Tecfidera Growth On a Rapid Transit

Drugs.com has released the latest U.S. drug sales data. While the ranking of the top three drugs by sales — Abilify, Nexium and Humira — remains the same, Lilly’s Cymbalta drops from fourth to seventh and forfeits close to $319 million in sales due to generic availability. Nexium’s growth tapers too, possibly due to looming […]